CAMBRIDGE, Mass. , July 28, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its second quarter 2020 financial results before the market opens on Thursday,...

- SYNB1891 is currently being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors or lymphoma - CAMBRIDGE, Mass. , June 1, 2020 /PRNewswire/ --  Synlogic, Inc., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel,...

Live Webcast Scheduled to Begin at 12.30 pm ET Today CAMBRIDGE, Mass. , May 27, 2020 /PRNewswire/ --  Synlogic (Nasdaq: SYBX) today will host its first Virtual R&D Event which will include presentations from members of the Synlogic executive team providing an in-depth review of Synlogic's Synthetic...

CAMBRIDGE, Mass. , May 21, 2020 /PRNewswire/ --  Synlogic (Nasdaq: SYBX) announced today that the company will host a Virtual R&D Event at 12:30 pm ET on Wednesday, May 27th, 2020 . The event will provide an in-depth review of Synlogic's Synthetic Biotic platform and programs for the treatment of...

CAMBRIDGE, Mass. , May 21, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the termination of its collaboration with AbbVie, a global, research-based biopharmaceutical...

-Cash and investments of $114 million provide runway into 2022 - -Company will host virtual R&D event highlighting progress in its Synthetic Biotic platform and programs on Wednesday, May 27, 2020 - - Company will host a conference call at 8:00 am ET today - CAMBRIDGE, Mass....

CAMBRIDGE, Mass. , May 4, 2020 /PRNewswire/ --  Synlogic, Inc.  (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the Company will release its first quarter 2020 financial results before the market...

CAMBRIDGE, Mass. , March 30, 2020 /PRNewswire/ --  Synlogic, Inc.  (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines called Synthetic Biotic ™  medicines, today provided an update on its business operations and expected...

- Synlogic ended 2019 with approximately $127 million in cash and investments, which provides runway into 2022 - - Company will host a conference call at 5:00 pm ET today - CAMBRIDGE, Mass. , March 12, 2020 /PRNewswire/ --  Synlogic, Inc.  (Nasdaq: SYBX), a clinical stage company applying synthetic...

CAMBRIDGE, Mass. , March 11, 2020 /PRNewswire/ --  Synlogic (Nasdaq: SYBX) announced today that Richard Riese , M.D., Ph.D., Synlogic's chief medical officer, will present at the Chardan Microbiome Medicines Summit at Noon ET on Monday, March 16 th , 2020. This is a virtual event....

CAMBRIDGE, Mass. , March 5, 2020 /PRNewswire/ --  Synlogic, Inc.  (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the Company will release its fourth quarter and full year 2019 financial results...

CAMBRIDGE, Mass. , Feb. 18, 2020 /PRNewswire/ --  Synlogic (Nasdaq: SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic's president and chief executive officer, will participate in the following upcoming investor conferences: 9th Annual SVB Leerink Global Healthcare Conference on...